MC4R agonist · FDA approved.
PT-141 (bremelanotide, Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist — the direct research-and-development successor to Melanotan II. FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Supplied as research-grade material with 3rd-party HPLC verification and full Certificate of Analysis per lot.
PT-141 (bremelanotide, Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist — the direct research-and-development successor to Melanotan II. FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Agonist of central melanocortin receptors with preference for MC4R. Published literature describes CNS mechanism of action (vs. peripheral/vascular mechanisms typical of PDE5 inhibitors). Phase 3 trials demonstrated improvement in HSDD measures leading to approval.
FDA-approved as Vyleesi (Palatin / AMAG Pharmaceuticals, 2019) for HSDD in premenopausal women. Research-grade material is for non-clinical research use only.
The above summarizes published research literature. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
PT-141 (Bremelanotide) is a 7-residue peptide with molecular formula C50H68N14O10 and molecular weight of approximately 1,025.2 Da.
The full structural data and release specifications are in the Compound Profile section above. Every lot ships with an independently verified Certificate of Analysis.
Each lot is independently verified by a 3rd-party analytical laboratory (STERIS Labs, Alcami Analytical, or equivalent) before release. Release specification is HPLC purity ≥ 99.5% (typical > 99.8%), mass spectrometry identity match within ±0.5 Da, water content < 5.0% Karl Fischer, and endotoxin < 0.25 EU/mL by LAL (USP <85>).
Look up the full COA for your lot at coa-lookup.html.
All compounds ship at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way. Tracked; signature not required.
Store unopened lyophilized product at 2–8°C protected from light. Once reconstituted, most peptides are stable at 2–8°C for approximately 28 days (compound-dependent).
FDA-approved as Vyleesi (Palatin / AMAG Pharmaceuticals, 2019) for HSDD in premenopausal women. Research-grade material is for non-clinical research use only.
All PeptideBros compounds are sold strictly as chemical reference materials for in-vitro laboratory research. They are not for human consumption.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.